Annual report pursuant to Section 13 and 15(d)

Disclosure of Prior Period Financial Statement Immaterial Errors (Summary of Reclassifications) (Details)

v3.21.2
Disclosure of Prior Period Financial Statement Immaterial Errors (Summary of Reclassifications) (Details) - USD ($)
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating expense:    
Cost of goods sold $ 1,462,000 $ 703,000
Research and Development 9,989,000 3,573,000
General and administrative 22,031,000 11,365,000
Total operating expenses 32,020,000 14,938,000
Eliminations [Member]    
Operating expense:    
Research and Development (1,341,000) (1,698,000)
General and administrative (983,000) (760,000)
Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold 425,000 640,000
Research and Development 2,960,000 492,000
General and administrative 13,429,000 5,355,000
Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold 1,037,000 63,000
Research and Development 8,370,000 4,779,000
General and administrative $ 9,585,000 6,770,000
Statement of Operations Reclassifications [Member]    
Operating expense:    
Cost of goods sold   703,000
Research and Development   3,573,000
General and administrative   11,365,000
Total operating expenses   $ 15,641,000
Cost of goods sold, % change   100.00%
Research and Development, % change   11.00%
General and administrative, % change   (9.00%)
Statement of Operations Reclassifications [Member] | As Reported [Member]    
Operating expense:    
Research and Development   $ 3,213,000
General and administrative   12,428,000
Total operating expenses   15,641,000
Statement of Operations Reclassifications [Member] | Reclassification, Adjustment [Member]    
Operating expense:    
Cost of goods sold   703,000
Research and Development   360,000
General and administrative   (1,063,000)
Segment Reporting Reclassifications [Member]    
Operating expense:    
Cost of goods sold   703,000
Research and Development   3,573,000
General and administrative   11,365,000
Segment Reporting Reclassifications [Member] | Eliminations [Member]    
Operating expense:    
Research and Development   (1,698,000)
General and administrative   (760,000)
Segment Reporting Reclassifications [Member] | Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold   640,000
Research and Development   491,000
General and administrative   5,356,000
Segment Reporting Reclassifications [Member] | Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold   63,000
Research and Development   4,780,000
General and administrative   6,769,000
Segment Reporting Reclassifications [Member] | As Reported [Member]    
Operating expense:    
Research and Development   3,213,000
General and administrative   12,428,000
Segment Reporting Reclassifications [Member] | As Reported [Member] | Eliminations [Member]    
Operating expense:    
Research and Development   (1,698,000)
General and administrative   (760,000)
Segment Reporting Reclassifications [Member] | As Reported [Member] | Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]    
Operating expense:    
Research and Development   1,106,000
General and administrative   5,381,000
Segment Reporting Reclassifications [Member] | As Reported [Member] | Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]    
Operating expense:    
Research and Development   3,805,000
General and administrative   $ 7,807,000